3 World-Renowned Sleep Apnea Experts Present New Benefits of PAP Therapies at ATS 2023
- France’s Jean-Louis Pépin and Germany’s Holger Woehrle presented studies in which treating OSA with CPAP lowered all-cause mortality for PAP vs. non-PAP users with OSA
- Germany’s Michael Arzt presented new evidence that treating CSA with ASV* caused “a significant and clinically relevant improvement in disease-specific QoL, daytime sleepiness, and quality of sleep”
WASHINGTON, May 25, 2023 (GLOBE NEWSWIRE) -- Renowned medical experts at the American Thoracic Society International Conference unveiled new evidence that demonstrates treating obstructive sleep apnea (OSA) with positive airway pressure (PAP) therapy lowers all-cause mortality for patients. In addition, a late-breaking abstract showed treating central sleep apnea (CSA) caused a “significant and clinically relevant improvement” in their symptoms and quality of life. The studies were among 24 supported by ResMed (NYSE: RMD, ASX: RMD).
Treating OSA with PAP lowered all-cause mortality in France, Germany
Two headline studies presented at ATS showed an association between PAP treatment for OSA and lower all-cause mortality. One is an analysis of over 22,000 anonymized German patients diagnosed with OSA – roughly half using PAP, the other not. The study, led and presented by German sleep researcher Holger Woehrle, concluded PAP treatment for OSA is associated with a .
The other is an analysis of over 100,000 deidentified French patients who previously stopped but restarted PAP to treat OSA – roughly two-thirds were still using PAP one year later, the other one-third stopped a second time. The study, led and presented by French sleep researcher Jean-Louis Pépin and part of ResMed’s broader landmark ALASKA study, found “ in individuals who continued using CPAP after therapy resumption.”
These studies build on a 2022 ResMed ALASKA study published in CHEST that found people with OSA who continued PAP over a three-year period were than those who didn’t.
Treating CSA with ASV improved quality of life, symptoms over 1 year
A third major finding came out of READ-ASV, the largest prospective registry investigating the clinical use and effects of adaptive-servo ventilation (ASV) in a real-world cohort with central sleep apnea. Led and presented by German sleep researcher Michael Arzt, this prospective, multicenter, and multinational study of 847 patients concluded that first-time ASV users with central sleep apnea “ in disease-specific quality of life, daytime sleepiness, and quality of sleep.”*
“Combined, these studies by globally renowned researchers emphasize not only the effectiveness of PAP and specifically ASV therapy for patients who need them, but how better sleep and breathing is vitally connected to our overall health,” said Carlos M. Nunez, M.D., ResMed Chief Medical Officer.
An estimated 936 million people worldwide have obstructive sleep apnea,1 a chronic disease in which throat muscles relax during sleep, constricting airflow. As a result, the body jolts to awaken and take a breath, causing dozens to hundreds of sleep interruptions per night. An estimated 5–10% of all people with sleep-disordered breathing have central sleep apnea,2 wherein the brain stops sending signals to the body’s breathing muscles during sleep, resulting in similar symptoms. All sleep apnea sufferers often aren’t aware of these waking episodes, and 80% remain undiagnosed.3
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
| For Media | For Investors | |
| Kristin Deuber | Amy Wakeham | |
| Rowena Kelley | ||
1 Benjafield AV et al. Lancet Resp Med 2019
2 Roberts EG at al. Curr Neurol Neurosci Rep 2022
3 Young T et al. Sleep 1997
* ASV therapy is contraindicated in patients with chronic, symptomatic heart failure (NYHA 2-4) with reduced left ventricular ejection fraction (LVEF ≤45%) and moderate to severe predominant central sleep apnea.
